Document is current
Any future updates will be listed below
-
Authors
Shaum, James B. https://orcid.org/0000-0003-1664-1091
Muñoz i Ordoño, Miquel https://orcid.org/0009-0003-4391-6393
Steen, Erica A.
Wenge, Daniela V. https://orcid.org/0000-0002-0064-9104
Cheong, Hakyung https://orcid.org/0009-0001-3330-3126
Janowski, Jordan https://orcid.org/0000-0002-6990-5719
Hunkeler, Moritz https://orcid.org/0000-0003-0246-1188
Bilotta, Eric M. https://orcid.org/0000-0001-7609-3037
Rutter, Zoe J.
Barta, Paige A.
Thornhill, Abby M.
Milosevich, Natalia
Hargis, Lauren M.
Bishop, Timothy R.
Carter, Trever R. https://orcid.org/0000-0001-5938-4043
da Camara, Bryce https://orcid.org/0009-0002-2327-7240
Hinterndorfer, Matthias https://orcid.org/0000-0003-2435-4690
Dada, Lucas https://orcid.org/0000-0001-5846-0219
He, Wen-Ji
Offensperger, Fabian
Furihata, Hirotake
Schweber, Sydney R. https://orcid.org/0009-0004-2141-7224
Hatton, Charlie https://orcid.org/0000-0001-9903-4291
Wen, Yanhe
Cravatt, Benjamin F. https://orcid.org/0000-0001-5330-3492
Engle, Keary M. https://orcid.org/0000-0003-2767-6556
Donovan, Katherine A. https://orcid.org/0000-0002-8539-5106
Melillo, Bruno https://orcid.org/0000-0002-9708-5287
Kitamura, Seiya
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
Armstrong, Scott A. https://orcid.org/0000-0002-9099-4728
Fischer, Eric S. https://orcid.org/0000-0001-7337-6306
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
Erb, Michael A. https://orcid.org/0000-0001-9993-3481
- License Information
-
More Information
Article History
Received: 22 October 2025
Accepted: 18 December 2025
First Online: 16 February 2026
Competing interests
: M.A.E. and S.K. are inventors on a patent application related to SR-0813 and TM-7. M.A.E., E.A.S. and J.B.S. are inventors on a patent application related to dHTC1. M.A.E. holds equity in Nexo Therapeutics and serves on their scientific advisory board (SAB). G.E.W. is a scientific founder and shareholder of Proxygen and Solgate and is on the SAB of Proxygen. He also holds equity in Cellgate Therapeutics and Nexo Therapeutics and serves on the SAB of Nexo Therapeutics. The G.E.W. lab has received research funding from Pfizer. E.S.F. is a founder, SAB member and equity holder of Civetta Therapeutics, Proximity Therapeutics, Neomorph (also on the board of directors), Stelexis Biosciences and Anvia Therapeutics (also on the board of directors). He is an equity holder and SAB member of Avilar Therapeutics, Photys Therapeutics and Ajax Therapeutics and an equity holder in Lighthorse Therapeutics and CPD4 (also on the board of directors). E.S.F. is a consultant to Novartis, EcoR1 Capital and Deerfield. The E.S.F. lab receives or has received research funding from Deerfield, Novartis, Ajax, Interline, Bayer and Astellas. A.C. is a cofounder and shareholder of Amphista Therapeutics, a company that develops targeted protein degradation platforms. The A.C. laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KgaA, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne. A.C. is on the SAB of ProtOS Bio. B.F.C. and B.M. are founders and/or scientific advisors to Magnet Biomedicine. K.A.D. receives or has received consulting fees from Neomorph and Kronos Bio. S.A.A. has been a consultant and/or shareholder for Neomorph, C4 Therapeutics, AstraZeneca, Accent Therapeutics, Hyku Therapeutics and Stelexis Therapeutics. S.A.A. has received research support from Janssen and Syndax. S.A.A. is an inventor on a patent related to MENIN inhibition WO/2017/132398A1. The other authors declare no competing interests.
